Center for Amyloidosis, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA.
Heart Fail Rev. 2022 Sep;27(5):1549-1557. doi: 10.1007/s10741-021-10159-w. Epub 2021 Sep 1.
Clinical heart failure, restrictive cardiomyopathy, and arrhythmias are hallmark features of amyloid cardiomyopathy. In contrast to the advancements in targeted therapies, there is a general lack of evidence-based practice guidelines for clinical management of amyloid cardiomyopathy. In this review, we review the role of routine medical therapy in amyloid cardiomyopathy, from heart failure management to orthostatic hypotension, atrial arrhythmias, thromboembolic complications, and prevention of sudden death. We conclude by discussing approaches to patients with end-stage disease.
临床心力衰竭、限制型心肌病和心律失常是淀粉样心肌病的标志性特征。与靶向治疗的进展相比,淀粉样心肌病的临床管理缺乏循证实践指南。在这篇综述中,我们回顾了常规医学治疗在淀粉样心肌病中的作用,从心力衰竭管理到直立性低血压、房性心律失常、血栓栓塞并发症和预防猝死。最后,我们讨论了终末期疾病患者的处理方法。